CD300A and neoplasm: In vivo analyses also showed that, although tumor growth was significantly larger and the survival rate was significantly shorter for B16 melanoma-injected Myd88−/−;Cd300a−/− mice compared with B16-injected Myd88−/− mice, tumor development and survival did not differ between ticam-1−/−;Cd300a−/− and ticam-1−/− mice (Figure 5G-J).